Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

RP L301

Next Previous
Drug Profile

RP L301

Alternative Names: LV RP-L301; RP-L301

Latest Information Update: 22 Apr 2026

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Centro de Investigacion Biomedica en Red de Enfermedades Raras; CIEMAT; Instituto de Investigacion Sanitaria Fundacion Jimenez Diaz
  • Developer Rocket Pharmaceuticals
  • Class Antianaemics; Gene therapies; Pyruvates
  • Mechanism of Action Gene transference; Pyruvate kinase replacements
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Pyruvate kinase deficiency of red cells
  • New Molecular Entity No
  • Available For Licensing Yes

Highest Development Phases

  • Phase II Pyruvate kinase deficiency of red cells

Most Recent Events

  • 22 Apr 2026 RP L301 is available for licensing as of 22 Apr 2026. https://rocketpharma.com/our-disease-focus/
  • 20 Oct 2025 Rocket Pharmaceuticals completes Phase-I clinical trials in Pyruvate kinase deficiency of red cells (In children, In adults, In adolescents) in USA and Spain (IV) (EudraCT2019-001656-19) (NCT04105166)
  • 28 Oct 2024 No recent reports of development identified for phase-I development in Pyruvate kinase deficiency of red cells(In adolescents, In children, In adults) in Spain (IV, Infusion)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top